Related Experiment Videos
Anticonvulsant activity and neurotoxicity of piperonyl butoxide in mice
Abstract:
Piperonyl butoxide, a microsomal monooxygenase inhibitor, administered intraperitoneally to mice exerts peak anti-maximal electroshock activity and peak neurotoxicity at 5 and 7h, respectively. The median neurotoxic dose is 1,690 mg/kg. In the maximal electroshock seizure test, the median effective dose (ED50) is 457 mg/kg and the protective index (PI) is 3.69. In the subcutaneous pentylenetetrazol test, the ED50 is 443 mg/kg and the PI is 3.81. Piperonyl butoxide prevents seizure spread and elevates seizure threshold. Its PI compares favorably with PIs of clinically useful anticonvulsants.
Insights
Piperonyl butoxide demonstrates anticonvulsant properties by preventing seizure spread and elevating seizure threshold in mice. Its protective index suggests potential as an effective anti-seizure medication.
Area of Science:
- Pharmacology
- Neuroscience
- Toxicology
Background:
- Piperonyl butoxide is a known inhibitor of microsomal monooxygenase.
- Understanding its effects on seizure activity and neurotoxicity is crucial for potential therapeutic applications.
Purpose of the Study:
- To evaluate the anticonvulsant efficacy of piperonyl butoxide.
- To assess the neurotoxic profile and determine the protective index (PI) in mouse models.
Main Methods:
- Administered piperonyl butoxide intraperitoneally to mice.
- Assessed anti-maximal electroshock (AME) activity and neurotoxicity over time.
- Determined median effective dose (ED50) and median neurotoxic dose (TD50) in maximal electroshock seizure and subcutaneous pentylenetetrazol tests.
Main Results:
- Peak anti-maximal electroshock activity observed at 5 hours; peak neurotoxicity at 7 hours.
- Median effective dose (ED50) for anticonvulsant activity was 457 mg/kg (maximal electroshock) and 443 mg/kg (pentylenetetrazol).
- Median neurotoxic dose was 1,690 mg/kg, yielding protective indices (PI) of 3.69 and 3.81, respectively.
Conclusions:
- Piperonyl butoxide effectively prevents seizure spread and elevates seizure threshold.
- The protective indices of piperonyl butoxide compare favorably with those of clinically used anticonvulsants, indicating a promising therapeutic potential.